Varsha Rao

Varsha Rao writes from a position most angels never reach. As former CEO of Nurx, she built and ran one of the most consequential telehealth companies of the last decade, navigating regulated prescribing, complex women’s health workflows, and enterprise-scale payer relationships in real life rather than in slide decks. She invests as a Sequoia Scout and on her own, and her checks tend to land in early-stage digital health companies and enterprise AI systems where her operational pattern recognition is actually useful. Her recent reach into companies like Ema, on the enterprise AI side, is part of a deliberate widening beyond pure healthtech.

The thesis sits at the crossing of women’s and reproductive health, AI/ML in healthcare, and enterprise AI more broadly. On the healthcare side, that means companies addressing women’s health gaps, reproductive care, hormone and fertility care, and adjacent care models that have to navigate prescribing, insurance, and direct-to-consumer mechanics simultaneously. On the AI side, she tends to back enterprise-grade systems where her experience scaling operations, hiring senior teams, and handling regulated workflows is a differentiated form of help. The portfolio mix reflects that range without being scattered.

Checks run $25k-$100k at pre-seed and seed. That is firmly in angel territory, and founders should treat her as a high-signal early supporter rather than a round lead. Geographically, she is based in San Francisco and most active in the US, with particular density in Bay Area and New York digital health. The Sequoia Scout relationship matters here: a Rao check often comes with the implicit signal that the deal has been seen by Sequoia’s broader network, and that signal can pull other angels and seed funds onto the cap table.

The operator background is the core of what founders are buying. She has personally run a healthcare company through scaling pains, regulatory complexity, and the operational reality of consumer health businesses that have to also satisfy clinical and pharmacy partners. She tends to be useful on questions that founders cannot get good answers to elsewhere: how to set up a clinician network, how to think about state-by-state telehealth licensing, how to structure a customer support organization for sensitive care, how to build a senior team in a venture-funded healthcare company.

For founders, the practical read is that Rao is among the more useful operator-angels in digital health, particularly for women’s health, reproductive care, and AI-enabled care delivery. She is less useful for pure therapeutics, for hardware businesses, or for founders who do not need an operator’s perspective. Engagement style is selective and concentrated: she does not invest at scale and tends to stay close to the small number of companies she backs. Founders pitching her should expect specific, operationally grounded questions and should bring real answers rather than narratives. Founders who want a thoughtful, regulated-healthcare-fluent angel with brand-name network access will find her one of the better options on a small list.